Dr. Liang Peng, founder of Clover Biology： realize the early listing of vaccine products in COVID-19 and contribute China’s strength to the global epidemic prevention.
Cover journalist Yang Jinzhu Photography Lei Yuandong
What is innovation? Different people may give different answers.
In Dr. Liang Peng’s view, "innovation should not only see what others can see, but also think of what others can’t think of, and boldly try what others have never done before."
In 2007, Liang Peng, who has a long reputation in the field of life sciences, returned to China to start a business and founded clover biology in Chengdu. After more than ten years’ development, clover has made its mark in COVID-19 vaccine track.
Liang Peng, founder, chairman and chief scientific officer of Sichuan Clover Biopharmaceutical Co., Ltd.
On March 29th, 2022, the awarding ceremony of the "Model China 2021 Top Ten Economic Influential People in Sichuan" was held in Shuangliu District, Chengdu. Liang Peng, founder, chairman and chief scientific officer of Sichuan Clover Biopharmaceutical Co., Ltd., was listed as "Top Ten New Economic Leaders in Sichuan in 2021".
"It is a great honor that the innovative technology and achievements of clover biology have been recognized, which has strengthened my scientific belief in adhering to source innovation." Facing the honor, Dr. Liang Peng said, "As a global innovative biotechnology company, the future clover will continue to be firm and committed to giving mankind a healthier future through transformative science."
Return to China for business
"Contribute to the development of biopharmaceutical technology in China"
A decision made 15 years ago, Liang Peng’s life is closely linked with clover creatures.
Liang Peng graduated from the Department of Biology in Peking University. After completing postdoctoral research at Harvard Medical School in the United States, he worked as an assistant professor at Vanderbilt University, known as "Southern Harvard". In the meantime, he invented technologies such as gene differential display, and successfully founded his first biotechnology company in Boston.
But in 2007, he made a decision-to return to China to start a business. "I hope to use the protein trimerization platform technology I invented to develop innovative vaccines and biotherapy in China to benefit patients and realize the industrialization of trimerization technology." Liang Peng said.
Liang Peng grew up in Chengdu, Sichuan, and chose to return to China to start a business, hoping to be closer to his family. "I want to share my achievements in every step of scientific research with my father, even if I encounter setbacks, I know he will encourage me." When he was a child, he learned from his father’s laboratory in West China Medical College and chose the biology department of Peking University and his career direction.
So, he firmly returned to his hometown of Chengdu and founded the clover creature. Liang Peng said that clover contains good intentions. In his view, clover not only vividly represents the trimerization technology platform in protein, but also has the meaning of luck. "My initial intention is to bring the hope and luck of life to patients and their families with the invention of advanced biopharmaceutical technology."
After years of development, clover has accelerated the development of new vaccines and biotherapy based on the trimerization technology platform in protein, and has a strong pipeline of new vaccines and biotherapy candidate products for treating infectious diseases, cancers and autoimmune diseases, as well as a self-owned and commercialized biopharmaceutical production base in Changxing County, Zhejiang Province.
Award ceremony site
facing to the world
"Let the COVID-19 vaccine made in China benefit the whole world"
The clinical data obtained from COVID-19 vaccine developed by clover have attracted much attention. Liang Peng said that in the fifth month after the second dose of basic immunization, the candidate vaccine of Clover Bio-COVID-19 was very effective in preventing severe COVID-19 caused by Covid-19 strain, and it was also very effective in preventing COVID-19 who needed hospitalization.
He said that more and more clinical evidence shows that the COVID-19 candidate vaccine of clover as a universal COVID-19 booster vaccine may induce a significant and broad-spectrum neutralizing immune response to mutant strains including Omicron, and combined with its good safety, immunogenicity and stability under standard refrigeration conditions, "we believe that it will become an important universal COVID-19 booster vaccine in China and the world."
On November 5, 2021, clover was officially listed on the Hong Kong Stock Exchange. It is reported that before the IPO, Clover Bio won the full support of many top investment institutions, including Gaochun, Temasek, Haisong Capital and Aobo Capital.
site of activity
look into the future
"Contribute China’s strength to the global anti-epidemic"
This time, he was awarded the title of "Top Ten New Economic Leaders in Sichuan in 2021". Liang Peng said that it is both recognition and a new beginning.
"As a vaccine development enterprise in COVID-19, we will actively promote the development of candidate vaccines in COVID-19, and accelerate the commercial production and listing of vaccines in COVID-19, contributing to the global fight against epidemic." Liang Peng said.
Liang Peng revealed that clover will further improve its production infrastructure, prepare for global commercialization, and strive to improve the production capacity of domestic and foreign markets. At the same time, we will continue to intensify R&D and innovation to build global innovation strength.
Looking forward to the future, Liang Peng said that Sichuan has created a broad development space, high-quality industrial ecology and a good business environment for the majority of biomedical enterprises, and clover creatures have fully benefited from the policy support, financial support, service guarantee and intelligence introduction environment here. In the future, we look forward to working closely with governments at all levels in Sichuan to seek greater development together.
Reporting/feedback